Biotech is a sector that can make investors rich like no other, and even the biggest players in the business aren't afraid of jumping out to big gains. Take Gilead Sciences (NASDAQ:GILD), one of biotech's top names that has seen its stock roar to gains of more than 87% year-to-date.
Gilead has long dominated the HIV treatment space, but the company's made big moves this year to set it and its investors up for a great future. From the sturdy rise of new HIV compound Stribild to the approval of a new oral hepatitis-C regimen, Gilead hasn't stopped to slow down ever since January kicked off.
But can Gilead's moves this year make you rich for the long term? In the video below, Fool contributor Dan Carroll takes you through three of Gilead's biggest drivers behind its great year -- and what these mean for the stock's long-term potential.
Fool contributor Dan Carroll has no position in any stocks mentioned. The Motley Fool recommends Gilead Sciences. Try any of our Foolish newsletter services free for 30 days. We Fools may not all hold the same opinions, but we all believe that considering a diverse range of insights makes us better investors. The Motley Fool has a disclosure policy.